Skip to main content
OpenTrials
Completed

NCT Number: NCT01086436

Study to Evaluate the Safety of Rotarix™ in Chinese Children

The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy children aged 2 to 6 years in China.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Liucheng County, Guangxi, 545200, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians (Legally acceptable representative) can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female subject of Chinese origin, between, and including, 2 and 6 years of age at the time of vaccination.
  • Written informed consent obtained from the parent or legally acceptable representative of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs six months prior to the vaccine dose.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within 14 days of the Human Rotavirus vaccine or placebo with the exception of the routine childhood vaccines. Routine childhood vaccines must not be administered on the same day as the Human Rotavirus vaccine or placebo.
  • Administration of immunoglobulins and/or any blood products since birth within three months preceding the study vaccine or planned administration during the study period.
  • Major congenital defects or serious chronic illness.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of Intusussception or any chronic gastrointestinal disease that would predispose for Intusussception including any uncorrected congenital malformation of the gastrointestinal tract.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment.
  • Gastroenteritis within 7 days preceding the study vaccine or placebo administration.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product..
  • Child in care.

Treatment and study plan

Rotarix ™

Biological

Oral, single dose

Placebo

Biological

Oral, single dose

Primary outcomes

  1. Occurrence of each solicited symptom

    Time frame: Within the 8-day (Day 0 - Day 7) follow-up period after the vaccine dose.

Secondary outcomes

  1. Occurrence of unsolicited adverse events

    Time frame: Within the 31 days (Day 0 - Day 30) after the vaccine dose.

  2. Occurrence of serious adverse events

    Time frame: Throughout the study period following the vaccine dose.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Mar 15, 2010
Registry last updated
May 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.